Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.51 |
| ▸ | F11 | P03951 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | HMGCR | P04035 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18654290 | 1.00 | PTPN1 (0.51) | PTPN1F11USP2MEN1POLB | |
| SCHEMBL20739194 | 0.92 | USP2 (0.54) | PTPN1F11USP2MEN1POLB | |
| SCHEMBL24378511 | 0.92 | USP2 (0.54) | PTPN1F11USP2MEN1POLB | |
| SCHEMBL23895306 | 0.92 | USP2 (0.54) | PTPN1F11USP2MEN1POLB | |
| SCHEMBL14005673 | 0.92 | USP2 (0.54) | PTPN1F11USP2MEN1POLB | |
| SCHEMBL18654211 | 0.91 | LGALS3 (0.46) | PTPN1F11USP2MEN1POLB | |
| SCHEMBL16360807 | 0.91 | TSHR (0.47) | PTPN1F11USP2MEN1POLB | |
| SCHEMBL21754881 | 0.91 | USP2 (0.55) | PTPN1F11USP2MEN1POLB | |
| SCHEMBL21754836 | 0.91 | USP2 (0.55) | PTPN1F11USP2MEN1POLB | |
| SCHEMBL12222446 | 0.91 | USP2 (0.55) | PTPN1F11USP2MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266609-B2 | Immunomodulating beta-1,6-D-glucans | INNATE BIOTHERAPEUTICS, LLC (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170081428-A1 | IMMUNOMODULATING BETA-1,6-D-GLUCANS | INNATE BIOTHERAPEUTICS, LLC | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266609-B2 | Immunomodulating beta-1,6-D-glucans | IFNG, FUT6, LGALS1 | PTPN1 797/4885F11 866/4885USP2 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.